AbbVie Inc. entered an agreement to license up to three next-generation cancer immunotherapies from Turnstone Biologics Inc.

AbbVie can obtain all global development and commercialization rights to Turnstone Biologics' Ad-MG1-MAGEA3, which is in two phase 1/2 clinical trials for multiple solid tumor indications both alone and in combination with an approved anti-PD-1 checkpoint inhibitor, as well as up to two research-stage candidates to be developed by Turnstone as part of the collaboration.

The research will use Turnstone's Maraba oncolytic viral immunotherapy to target a selective tumor-destroying oncolytic virus all the while acting as an immune-stimulating T-cell vaccine.

Financial terms of the deal were not disclosed. The transaction is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act.